5.07
price up icon3.79%   0.195
 
loading

Warum fällt Immunitybio Inc-Aktie (IBRX)?

Wir haben während der Handelssitzung 2024-11-20 einen Rückgang der Aktie Immunitybio Inc (IBRX) um 8.88% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!
2023-05-22:

IBRX's stock fell 6.06% related to the investigation claims against the company. The investigation focuses on whether IBRX issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ImmunityBio announced on May 11, 2023, that it "has received a complete response letter from the U.S. Food and Drug Administration ("FDA") on May 9, 2023 regarding its Biologics License Application ("BLA") for its product candidate, Anktiva™ (N-803) in combination with Bacillus Calmette-Guérin ("BCG"). The letter indicates that the FDA has determined that it cannot approve the BLA in its present form, and the FDA has made recommendations to address the issues raised."

https://www.accesswire.com/viewarticle.aspx?id=756192&lang=en

2023-05-11:

ImmunityBio’s stock price has fallen after receiving a response from the U.S. Food and Drug Administration (FDA). The FDA has rejected ImmunityBio’s application for Anktiva as a bladder cancer treatment.

https://investorplace.com/2023/05/why-is-immunitybio-ibrx-stock-down-54-today/

$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):